| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of 1Pediatrics, 2Internal Medicine, 3Microbiology, 5Biochemistry, and 4The Inflammation Program, Carver College of Medicine, University of Iowa and Iowa City Veterans Administration, Iowa City, Iowa
Submitted 3 November 2003 ; accepted in final form 25 April 2004
The expression of inducible antimicrobial peptides, such as human 
-defensin-2 (HBD-2) by epithelia, comprises a component of innate pulmonary defenses. We hypothesized that HBD-2 induction in airway epithelia is linked to pattern recognition receptors such as the Toll-like receptors (TLRs). We found that primary cultures of well-differentiated human airway epithelia express the mRNA for TLR-4, but little or no MD-2 mRNA, and display little HBD-2 expression in response to treatment with purified endotoxin ± LPS binding protein (LBP) and soluble CD14. Expression of endogenous MD-2 by transduction of airway epithelial cells with an adenoviral vector encoding MD-2 or extracellular addition of recombinant MD-2 both increased the responses of airway epithelia to endotoxin + LBP and sCD14 by >100-fold, as measured by NF-
B-luciferase activity and HBD-2 mRNA expression. MD-2 mRNA could be induced in airway epithelia by exposure of these cells to specific bacterial or host products (e.g., killed Haemophilus influenzae, the P6 outer membrane protein from H. influenzae, or TNF-
+ IFN-
). These findings suggest that MD-2, either coexpressed with TLR-4 or secreted when produced in excess of TLR-4 from neighboring cells, is required for airway epithelia to respond sensitively to endotoxin. The regulation of MD-2 expression in airway epithelia and pulmonary macrophages may serve as a means to modify endotoxin responsiveness in the airway.
cell surface molecules; mucosa; lung; inflammation
This article has been cited by other articles:
|
|
 |
|
  S. Hadina, J. P. Weiss, P. B. McCray Jr., K. Kulhankova, and P. S. Thorne MD-2-Dependent Pulmonary Immune Responses to Inhaled Lipooligosaccharides: Effect of Acylation State Am. J. Respir. Cell Mol. Biol., June 1, 2008; 38(6): 647 - 654. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Mizgerd Acute Lower Respiratory Tract Infection N. Engl. J. Med., February 14, 2008; 358(7): 716 - 727. [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Munford Sensing Gram-Negative Bacterial Lipopolysaccharides: a Human Disease Determinant? Infect. Immun., February 1, 2008; 76(2): 454 - 465. [Full Text] [PDF]
|
|
|
|
 |
|
 D. McClenahan, K. Hellenbrand, D. Atapattu, N. Aulik, D. Carlton, A. Kapur, and C. Czuprynski Effects of Lipopolysaccharide and Mannheimia haemolytica Leukotoxin on Bovine Lung Microvascular Endothelial Cells and Alveolar Epithelial Cells Clin. Vaccine Immunol., February 1, 2008; 15(2): 338 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Teghanemt, F. Re, P. Prohinar, R. Widstrom, T. L. Gioannini, and J. P. Weiss Novel Roles in Human MD-2 of Phenylalanines 121 and 126 and Tyrosine 131 in Activation of Toll-like Receptor 4 by Endotoxin J. Biol. Chem., January 18, 2008; 283(3): 1257 - 1266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Gradisar, M. M. Keber, P. Pristovsek, and R. Jerala MD-2 as the target of curcumin in the inhibition of response to LPS J. Leukoc. Biol., October 1, 2007; 82(4): 968 - 974. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Blau, K. Klein, I. Shalit, D. Halperin, and I. Fabian Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, JNK, and NF-{kappa}B activation in a cystic fibrosis epithelial cell line Am J Physiol Lung Cell Mol Physiol, January 1, 2007; 292(1): L343 - L352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Visintin, K. A. Halmen, N. Khan, B. G. Monks, D. T. Golenbock, and E. Lien MD-2 expression is not required for cell surface targeting of Toll-like receptor 4 (TLR4) J. Leukoc. Biol., December 1, 2006; 80(6): 1584 - 1592. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Machen Innate immune response in CF airway epithelia: hyperinflammatory? Am J Physiol Cell Physiol, August 1, 2006; 291(2): C218 - C230. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Tseng, J. Do, J. H. Widdicombe, and T. E. Machen Innate immune responses of human tracheal epithelium to Pseudomonas aeruginosa flagellin, TNF-{alpha}, and IL-1beta Am J Physiol Cell Physiol, March 1, 2006; 290(3): C678 - C690. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tuin, A. Huizinga-Van der Vlag, A.-M. M. A. van Loenen-Weemaes, D. K. F. Meijer, and K. Poelstra On the role and fate of LPS-dephosphorylating activity in the rat liver Am J Physiol Gastrointest Liver Physiol, February 1, 2006; 290(2): G377 - G385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Martin and C. W. Frevert Innate Immunity in the Lungs Proceedings of the ATS, December 1, 2005; 2(5): 403 - 411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Blais, S. G. Vascotto, M. Griffith, and I. Altosaar LBP and CD14 Secreted in Tears by the Lacrimal Glands Modulate the LPS Response of Corneal Epithelial Cells Invest. Ophthalmol. Vis. Sci., November 1, 2005; 46(11): 4235 - 4244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Savov, D. M. Brass, B. L. Lawson, E. McElvania-Tekippe, J. K. L. Walker, and D. A. Schwartz Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopolysaccharide Am J Physiol Lung Cell Mol Physiol, August 1, 2005; 289(2): L329 - L337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Pugin, S. Stern-Voeffray, B. Daubeuf, M. A. Matthay, G. Elson, and I. Dunn-Siegrist Soluble MD-2 activity in plasma from patients with severe sepsis and septic shock Blood, December 15, 2004; 104(13): 4071 - 4079. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
